
|Articles|October 1, 2003
Iris-claw phakic IOL found to be safe for treating hyperopia
Author(s)Cheryl Guttman
Stanford, CA-The phase III trial of the iris-claw phakic IOL (Artisan, Ophtec) for the treatment of hyperopia is now 2 years post- launch, and the short- and long-term results from the interim analyses are very encouraging, said Edward E. Manche, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Beyond the surface: Tackling complex dry eye cases
3
An Extreme Case of Demodex Blepharitis: From Misdiagnosis to Remarkable Recovery
4
Redefining glaucoma care: Where innovation meets clinical insight
5



















































.png)


